The company was founded as APREX Corporation (the name stands for `after prescription’) by Prof. John Urquhart in 1984, based in Fremont, California, near San Francisco. Aprex was the pioneer in medication adherence and, with its development of the Medication Event Monitoring Systems (MEMS®), led the way in describing patients’ adherence to medication.
In 1999, APREX was acquired by AARDEX Ltd. (“Advanced Analytical Research on Drug Exposure”), a Swiss company co-founded by Dr Métry and Dr John Urquhart in 1995.
AARDEX Group was acquired in 2012 by MeadWestvaco (MWV) Corporation, a global leader in packaging and packaging solutions with 15'000 employees worldwide, operating in 30 countries and serving customers in more than 100 nations.
AARDEX has changed name in 2015 after the merge between Rocktenn and MWV to become a Westrock company; WestRock being one of the world's largest paper and packaging companies with $15 billion in annual revenue and 42,000 employees in 30 countries.
In 2018, The Belgian-Swiss company AARDEX Group announced the completion of a management buyout (MBO) from owner WestRock for all activities covering Medication Event Monitoring System (MEMS®). The HQ is now located in Liège, Belgium.
The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is around 50%. A major surprise has been the finding that life-threatening diseases do not, ipso facto, enforce strict adherence. This fact became evident in the fields of organ transplantation, HIV-AIDS, and more recently in cancer chemotherapy.
Our objective is to continuously innovate to develop efficient solutions for this pervasive problem of striking magnitude in the healthcare system and in clinical trials.
Our mission is to develop and market eco-systems to measure, analyze, and implement patient medication adherence in clinical trials, research settings, and professional healthcare systems to support successful management of patients' adherence to medications.